Sotorasib confers durable benefit in lung cancer subset

Sotorasib exhibited durable efficacy among certain adults with locally advanced or metastatic non-small cell lung cancer, according to study results presented at American Association for Cancer Research Annual Meeting.
The agent also demonstrated a favorable safety profile among those with KRASG12C-mutated disease who progressed on prior therapies, 2-year follow-up of the CodeBreaK 100 trial showed.
The findings show sotorasib (Lumakras, Amgen) is an effective and safe therapy for patients with KRASG12C-mutated NSCLC, according to study author Grace K. Dy, MD, chief of thoracic oncology and

Sotorasib exhibited durable efficacy among certain adults with locally advanced or metastatic non-small cell lung cancer, according to study results presented at American Association for Cancer Research Annual Meeting.
The agent also demonstrated a favorable safety profile among those with KRASG12C-mutated disease who progressed on prior therapies, 2-year follow-up of the CodeBreaK 100 trial showed.
The findings show sotorasib (Lumakras, Amgen) is an effective and safe therapy for patients with KRASG12C-mutated NSCLC, according to study author Grace K. Dy, MD, chief of thoracic oncology and